Modulation of cGMP in Heart Failure: A New Therapeutic Paradigm View Full Text


Ontology type: schema:Chapter      Open Access: True


Chapter Info

DATE

2009

AUTHORS

Guido Boerrigter , Harald Lapp , John C. Burnett

ABSTRACT

Heart failure (HF) is a common disease that continues to be associated with high morbidity and mortality warranting novel therapeutic strategies. Cyclic guanosine monophosphate (cGMP) is the second messenger of several important signaling pathways based on distinct guanylate cyclases (GCs) in the cardiovascular system. Both the nitric oxide/soluble GC (NO/sGC) as well as the natriuretic peptide/GC-A (NP/GC-A) systems are disordered in HF, providing a rationale for their therapeutic augmentation. Soluble GC activation with conventional nitrovasodilators has been used for more than a century but is associated with cGMP-independent actions and the development of tolerance, actions which novel NO-independent sGC activators now in clinical development lack. Activation of GC-A by administration of naturally occurring or designer natriuretic peptides is an emerging field, as is the inhibition of enzymes that degrade endogenous NPs. Finally, inhibition of cGMP-degrading phosphodiesterases, particularly phosphodiesterase 5 provides an additional strategy to augment cGMP-signaling. More... »

PAGES

485-506

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-3-540-68964-5_21

DOI

http://dx.doi.org/10.1007/978-3-540-68964-5_21

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1050807301

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/19089342


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Animals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclic GMP", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme Activators", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Guanylate Cyclase", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Failure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Natriuretic Peptides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nitric Oxide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phosphodiesterase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Cytoplasmic and Nuclear", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Signal Transduction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Soluble Guanylyl Cyclase", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Cardiorenal Research Laboratory, Division of Cardiovascular Diseases Mayo Heart and Lung Research Center, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN, USA", 
          "id": "http://www.grid.ac/institutes/grid.66875.3a", 
          "name": [
            "Cardiorenal Research Laboratory, Division of Cardiovascular Diseases Mayo Heart and Lung Research Center, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Boerrigter", 
        "givenName": "Guido", 
        "id": "sg:person.01021616027.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01021616027.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiology, Helios-Klinikum Erfurt, Erfurt, Germany", 
          "id": "http://www.grid.ac/institutes/grid.491867.5", 
          "name": [
            "Department of Cardiology, Helios-Klinikum Erfurt, Erfurt, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lapp", 
        "givenName": "Harald", 
        "id": "sg:person.01134366154.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01134366154.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiorenal Research Laboratory, Division of Cardiovascular Diseases Mayo Heart and Lung Research Center, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN, USA", 
          "id": "http://www.grid.ac/institutes/grid.66875.3a", 
          "name": [
            "Cardiorenal Research Laboratory, Division of Cardiovascular Diseases Mayo Heart and Lung Research Center, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Burnett", 
        "givenName": "John C.", 
        "id": "sg:person.01001266776.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001266776.01"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2009", 
    "datePublishedReg": "2009-01-01", 
    "description": "Heart failure (HF) is a common disease that continues to be associated with high morbidity and mortality warranting novel therapeutic strategies. Cyclic guanosine monophosphate (cGMP) is the second messenger of several important signaling pathways based on distinct guanylate cyclases (GCs) in the cardiovascular system. Both the nitric oxide/soluble GC (NO/sGC) as well as the natriuretic peptide/GC-A (NP/GC-A) systems are disordered in HF, providing a rationale for their therapeutic augmentation. Soluble GC activation with conventional nitrovasodilators has been used for more than a century but is associated with cGMP-independent actions and the development of tolerance, actions which novel NO-independent sGC activators now in clinical development lack. Activation of GC-A by administration of naturally occurring or designer natriuretic peptides is an emerging field, as is the inhibition of enzymes that degrade endogenous NPs. Finally, inhibition of cGMP-degrading phosphodiesterases, particularly phosphodiesterase 5 provides an additional strategy to augment cGMP-signaling.", 
    "editor": [
      {
        "familyName": "Schmidt", 
        "givenName": "Harald H. H. W.", 
        "type": "Person"
      }, 
      {
        "familyName": "Hofmann", 
        "givenName": "Franz", 
        "type": "Person"
      }, 
      {
        "familyName": "Stasch", 
        "givenName": "Johannes-Peter", 
        "type": "Person"
      }
    ], 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-3-540-68964-5_21", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": {
      "isbn": [
        "978-3-540-68960-7", 
        "978-3-540-68964-5"
      ], 
      "name": "cGMP: Generators, Effectors and Therapeutic Implications", 
      "type": "Book"
    }, 
    "keywords": [
      "cyclic guanosine monophosphate", 
      "heart failure", 
      "development of tolerance", 
      "designer natriuretic peptide", 
      "guanylate cyclases", 
      "novel therapeutic strategies", 
      "new therapeutic paradigm", 
      "cGMP-degrading phosphodiesterases", 
      "soluble guanylate cyclases", 
      "high morbidity", 
      "natriuretic peptide", 
      "therapeutic augmentation", 
      "therapeutic strategies", 
      "therapeutic paradigm", 
      "cardiovascular system", 
      "sGC activators", 
      "GC activation", 
      "common disease", 
      "guanosine monophosphate", 
      "inhibition of enzymes", 
      "important signaling pathways", 
      "additional strategies", 
      "signaling pathways", 
      "inhibition", 
      "second messenger", 
      "activation", 
      "morbidity", 
      "failure", 
      "nitrovasodilators", 
      "mortality", 
      "disease", 
      "administration", 
      "action", 
      "augmentation", 
      "monophosphate", 
      "activator", 
      "pathway", 
      "peptides", 
      "phosphodiesterases", 
      "rationale", 
      "modulation", 
      "messenger", 
      "strategies", 
      "lack", 
      "tolerance", 
      "enzyme", 
      "cyclases", 
      "development", 
      "system", 
      "paradigm", 
      "NPs", 
      "field", 
      "century", 
      "distinct guanylate cyclases", 
      "nitric oxide/soluble GC", 
      "oxide/soluble GC", 
      "natriuretic peptide/GC", 
      "peptide/GC", 
      "Soluble GC activation", 
      "conventional nitrovasodilators", 
      "cGMP-independent actions", 
      "NO-independent sGC activators", 
      "clinical development lack", 
      "development lack", 
      "Activation of GC", 
      "endogenous NPs", 
      "Modulation of cGMP"
    ], 
    "name": "Modulation of cGMP in Heart Failure: A New Therapeutic Paradigm", 
    "pagination": "485-506", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1050807301"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-3-540-68964-5_21"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "19089342"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-3-540-68964-5_21", 
      "https://app.dimensions.ai/details/publication/pub.1050807301"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-01-01T19:17", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/chapter/chapter_304.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-3-540-68964-5_21"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-3-540-68964-5_21'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-3-540-68964-5_21'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-3-540-68964-5_21'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-3-540-68964-5_21'


 

This table displays all metadata directly associated to this object as RDF triples.

210 TRIPLES      23 PREDICATES      107 URIs      100 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-3-540-68964-5_21 schema:about N2510466bc300456db7fe2257525380f6
2 N3ef345fb24b5491d9f494e7527bf0433
3 N4686f006881c4231996ca180f2594498
4 N477ea418d3d246ac8a4d4caa2b404365
5 N6133e76665354833866830e9d30b7f82
6 N7f9a04b913994c9fa80c6cc20f8d30e5
7 N9b2a227af9de439ba1ae2e8567d6c500
8 N9e7a34016fb74e1a89798e7c9e908e3b
9 Na0337fb1a8144e7282f39a54e0020033
10 Ndf896bc58ec141d7abb0aef27faa877b
11 Ne64af437ea3247de8585a80a92ad3b4c
12 Nf79d894603084a77a6d028e5529928cf
13 Nf884745e88b24dc787504d3186df6571
14 anzsrc-for:11
15 anzsrc-for:1102
16 schema:author Nc3f0765cf277427fa482723b1fde8967
17 schema:datePublished 2009
18 schema:datePublishedReg 2009-01-01
19 schema:description Heart failure (HF) is a common disease that continues to be associated with high morbidity and mortality warranting novel therapeutic strategies. Cyclic guanosine monophosphate (cGMP) is the second messenger of several important signaling pathways based on distinct guanylate cyclases (GCs) in the cardiovascular system. Both the nitric oxide/soluble GC (NO/sGC) as well as the natriuretic peptide/GC-A (NP/GC-A) systems are disordered in HF, providing a rationale for their therapeutic augmentation. Soluble GC activation with conventional nitrovasodilators has been used for more than a century but is associated with cGMP-independent actions and the development of tolerance, actions which novel NO-independent sGC activators now in clinical development lack. Activation of GC-A by administration of naturally occurring or designer natriuretic peptides is an emerging field, as is the inhibition of enzymes that degrade endogenous NPs. Finally, inhibition of cGMP-degrading phosphodiesterases, particularly phosphodiesterase 5 provides an additional strategy to augment cGMP-signaling.
20 schema:editor Na52748afce7b45c78f65567b9b9663e6
21 schema:genre chapter
22 schema:inLanguage en
23 schema:isAccessibleForFree true
24 schema:isPartOf Nbddd118c88e3447b895ffbc2199132e8
25 schema:keywords Activation of GC
26 GC activation
27 Modulation of cGMP
28 NO-independent sGC activators
29 NPs
30 Soluble GC activation
31 action
32 activation
33 activator
34 additional strategies
35 administration
36 augmentation
37 cGMP-degrading phosphodiesterases
38 cGMP-independent actions
39 cardiovascular system
40 century
41 clinical development lack
42 common disease
43 conventional nitrovasodilators
44 cyclases
45 cyclic guanosine monophosphate
46 designer natriuretic peptide
47 development
48 development lack
49 development of tolerance
50 disease
51 distinct guanylate cyclases
52 endogenous NPs
53 enzyme
54 failure
55 field
56 guanosine monophosphate
57 guanylate cyclases
58 heart failure
59 high morbidity
60 important signaling pathways
61 inhibition
62 inhibition of enzymes
63 lack
64 messenger
65 modulation
66 monophosphate
67 morbidity
68 mortality
69 natriuretic peptide
70 natriuretic peptide/GC
71 new therapeutic paradigm
72 nitric oxide/soluble GC
73 nitrovasodilators
74 novel therapeutic strategies
75 oxide/soluble GC
76 paradigm
77 pathway
78 peptide/GC
79 peptides
80 phosphodiesterases
81 rationale
82 sGC activators
83 second messenger
84 signaling pathways
85 soluble guanylate cyclases
86 strategies
87 system
88 therapeutic augmentation
89 therapeutic paradigm
90 therapeutic strategies
91 tolerance
92 schema:name Modulation of cGMP in Heart Failure: A New Therapeutic Paradigm
93 schema:pagination 485-506
94 schema:productId Na7662c66b7a847509c9691869acf33bc
95 Nf284840ce412401a808d9542b360b92f
96 Nf750e5199dd84c66a49361ce096a3d92
97 schema:publisher N9318d3b72f8a4723996a42a4e513a5bc
98 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050807301
99 https://doi.org/10.1007/978-3-540-68964-5_21
100 schema:sdDatePublished 2022-01-01T19:17
101 schema:sdLicense https://scigraph.springernature.com/explorer/license/
102 schema:sdPublisher N95763fae41ec4e4abc6d89345a5346e2
103 schema:url https://doi.org/10.1007/978-3-540-68964-5_21
104 sgo:license sg:explorer/license/
105 sgo:sdDataset chapters
106 rdf:type schema:Chapter
107 N23648133f78c4985b79205f038775043 rdf:first sg:person.01134366154.06
108 rdf:rest N83d0ae671b9c436497e7f861c0485040
109 N2510466bc300456db7fe2257525380f6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Receptors, Cytoplasmic and Nuclear
111 rdf:type schema:DefinedTerm
112 N263b45ff9c234a788f6e1ca03304a757 schema:familyName Hofmann
113 schema:givenName Franz
114 rdf:type schema:Person
115 N3853fbcbc7084e0883c1c86ee2cf6023 rdf:first Nc488bf8c80704d2a91bb6eed6567cf2f
116 rdf:rest rdf:nil
117 N3ef345fb24b5491d9f494e7527bf0433 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Enzyme Inhibitors
119 rdf:type schema:DefinedTerm
120 N4686f006881c4231996ca180f2594498 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Enzyme Activators
122 rdf:type schema:DefinedTerm
123 N477ea418d3d246ac8a4d4caa2b404365 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Animals
125 rdf:type schema:DefinedTerm
126 N59f7e3519fc3468e9a3e216d9bd05558 rdf:first N263b45ff9c234a788f6e1ca03304a757
127 rdf:rest N3853fbcbc7084e0883c1c86ee2cf6023
128 N6133e76665354833866830e9d30b7f82 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Guanylate Cyclase
130 rdf:type schema:DefinedTerm
131 N7f9a04b913994c9fa80c6cc20f8d30e5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Phosphodiesterase Inhibitors
133 rdf:type schema:DefinedTerm
134 N83d0ae671b9c436497e7f861c0485040 rdf:first sg:person.01001266776.01
135 rdf:rest rdf:nil
136 N9318d3b72f8a4723996a42a4e513a5bc schema:name Springer Nature
137 rdf:type schema:Organisation
138 N95763fae41ec4e4abc6d89345a5346e2 schema:name Springer Nature - SN SciGraph project
139 rdf:type schema:Organization
140 N9a68b2434df8499891a68b817ccb4d03 schema:familyName Schmidt
141 schema:givenName Harald H. H. W.
142 rdf:type schema:Person
143 N9b2a227af9de439ba1ae2e8567d6c500 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Soluble Guanylyl Cyclase
145 rdf:type schema:DefinedTerm
146 N9e7a34016fb74e1a89798e7c9e908e3b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Cyclic GMP
148 rdf:type schema:DefinedTerm
149 Na0337fb1a8144e7282f39a54e0020033 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Nitric Oxide
151 rdf:type schema:DefinedTerm
152 Na52748afce7b45c78f65567b9b9663e6 rdf:first N9a68b2434df8499891a68b817ccb4d03
153 rdf:rest N59f7e3519fc3468e9a3e216d9bd05558
154 Na7662c66b7a847509c9691869acf33bc schema:name doi
155 schema:value 10.1007/978-3-540-68964-5_21
156 rdf:type schema:PropertyValue
157 Nbddd118c88e3447b895ffbc2199132e8 schema:isbn 978-3-540-68960-7
158 978-3-540-68964-5
159 schema:name cGMP: Generators, Effectors and Therapeutic Implications
160 rdf:type schema:Book
161 Nc3f0765cf277427fa482723b1fde8967 rdf:first sg:person.01021616027.74
162 rdf:rest N23648133f78c4985b79205f038775043
163 Nc488bf8c80704d2a91bb6eed6567cf2f schema:familyName Stasch
164 schema:givenName Johannes-Peter
165 rdf:type schema:Person
166 Ndf896bc58ec141d7abb0aef27faa877b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Natriuretic Peptides
168 rdf:type schema:DefinedTerm
169 Ne64af437ea3247de8585a80a92ad3b4c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Signal Transduction
171 rdf:type schema:DefinedTerm
172 Nf284840ce412401a808d9542b360b92f schema:name dimensions_id
173 schema:value pub.1050807301
174 rdf:type schema:PropertyValue
175 Nf750e5199dd84c66a49361ce096a3d92 schema:name pubmed_id
176 schema:value 19089342
177 rdf:type schema:PropertyValue
178 Nf79d894603084a77a6d028e5529928cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Heart Failure
180 rdf:type schema:DefinedTerm
181 Nf884745e88b24dc787504d3186df6571 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Humans
183 rdf:type schema:DefinedTerm
184 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
185 schema:name Medical and Health Sciences
186 rdf:type schema:DefinedTerm
187 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
188 schema:name Cardiorespiratory Medicine and Haematology
189 rdf:type schema:DefinedTerm
190 sg:person.01001266776.01 schema:affiliation grid-institutes:grid.66875.3a
191 schema:familyName Burnett
192 schema:givenName John C.
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001266776.01
194 rdf:type schema:Person
195 sg:person.01021616027.74 schema:affiliation grid-institutes:grid.66875.3a
196 schema:familyName Boerrigter
197 schema:givenName Guido
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01021616027.74
199 rdf:type schema:Person
200 sg:person.01134366154.06 schema:affiliation grid-institutes:grid.491867.5
201 schema:familyName Lapp
202 schema:givenName Harald
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01134366154.06
204 rdf:type schema:Person
205 grid-institutes:grid.491867.5 schema:alternateName Department of Cardiology, Helios-Klinikum Erfurt, Erfurt, Germany
206 schema:name Department of Cardiology, Helios-Klinikum Erfurt, Erfurt, Germany
207 rdf:type schema:Organization
208 grid-institutes:grid.66875.3a schema:alternateName Cardiorenal Research Laboratory, Division of Cardiovascular Diseases Mayo Heart and Lung Research Center, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN, USA
209 schema:name Cardiorenal Research Laboratory, Division of Cardiovascular Diseases Mayo Heart and Lung Research Center, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN, USA
210 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...